Michael S. Gossman, M.S., DABR, FAAPM
- Expert Witness - Medical malpractice, misadministration, medical event (Radiation Oncology, Radiology, Nuclear Medicine)
- Expert Witness - Radiation exposure, radiation dose, radioactivity and radiobiological calculations
- Expert Witness – Patent infringement (intellectual property all categories)
- Expert Witness – Medical physics, supervision of (medical physicist, dosimetrist, radiation therapist, radiologic technologist)
- Expert Witness - Termination of employment
, is a Board Certified Qualified Expert Medical Physicist
, an honorary Fellow of the American Association of Physicists in Medicine (AAPM)
, and currently the Chief Medical Physicist & Radiation Safety Officer (RSO) in Radiation Oncology
at Tri-State Regional Cancer Center in Ashland, KY.
Chief Gossman is extra-professionally an Accreditation Site Reviewer
for the American College of Radiation Oncology (ACRO)
and the American College of Radiology (ACR)
, was a 2-term Ohio River Valley Chapter President of the AAPM
, and formerly a Graduate School Professor of Clinical Medical Physics at Wright State University
. He is the highest ranking scientist in medicine and has been in the field for 17 years.
Chief Gossman's expertise involves the safe, effective and precise delivery of radiation to achieve the therapeutic result prescribed in patient care by radiation oncologists striving to treat cancer patients with particle accelerators and radioactive material. Extra-professionally, he is retired as the Interim Editor-in-Chief and Editorial Board Member
for the Medical Dosimetry Journal
, Editorial Board Member
for the Journal of Applied Clinical Medical Physics
, and served four years as a Medical Consultant to the U.S. Nuclear Regulatory Commission
Chief Gossman is directly and ultimately responsible for all technical and scientific aspects of cancer treatment. He directly supervises and oversees efforts from staff medical physicists, dosimetrists, radiation therapists and x-ray technologists. As an expert in radiation detector measurements, particle accelerator and radioactive material calibrations, and radioactive material handling, Mr. Gossman is a highly respected medical physicist by medical physicists nationally. He is also the owner of the Radiation Oncology Medical Physics consulting company Regulation Directive Medical Physics, LLC and employed extraprofessionally as a Senior Managing Scientist at Exponent, Inc. for medical device testing and expert witness efforts.
- Medical expert witness
- Medical consultant
- Legal consultant
- Review of: medical event, malpractice, and misadministration
- Regulatory compliance
- Investigation and audits
- Independent medical evaluation of the probable deterministic effects of radiation exposures
- Facility practice vs. standards review
- Accreditation preparation
- Shielding calculations
- Accelerator acceptance testing & commissioning
- Quality assurance
- Peer review of the Chief Medical Physicist
- Radiation measurements
- Radiation calculations
- Radiation safety
- Dose determination
- Calibration of medical accelerators
- Treatment planning
- Calculation of time and dose for treatment
- Handling, shipping, receiving, and storing radioactive material
- Calibrating radioactive material
- Regulatory compliance
- Interpretation of bioassay results and other data related to radiation exposure
- Calculation of internal and external radiation doses, as necessary
|Regulation Directive Medical Physics|
104 Hildeen Court
Russell, Kentucky, 41169
|Tri-State Regional Cancer Center|
Department of Radiation Oncology
706 23rd Street
Ashland, KY 41101
Cochlear implants, via direct electrical stimulation of the auditory nerve, allow the restoration of hearing and speech recognition in both adults and children having sensorineural deafness. These devices typically contain both extemal components (speech processor, microphone, transmitter) and intemal components (including the cochlear stimulator and electrode array), which are surgically placed under the skin behind the ear and in the cochlea.
Inadequate research exists regarding testing of a ventricular assist device (VAD) for susceptibility to radiation damage. Specifically, minimal data are available to radiation oncologists prescribing treatment plans for patients with an implanted VAD. As the number of implanted devices increases, patients requiring radiation at tissue sites near or at the device will increase.
Improved outcomes and quality of life of heart failure patients have been reported with the use of left ventricular assist devices (LVADs).
New research shows the effects of electron beams on implanted vascular access ports composed of plastic, determining how they impair the fluence of radiation around them.
Abstract. Object: Where no society-based or manufacturer guidance on radiation limits to neuromodulation devices is available, this research provides the groundwork for neurosurgeons and radiation oncologists who rely on the computerized treatment plan clinically for cancer patients.
Abstract-The medical community is advocating for progressive improvement in the design of implantable cardioverter-defibrillators and implantable pacemakers to accommodate elevations in dose limitation criteria.
Since the first commercial multichannel cochlear implant was marketed by Cochlear in 1985 (1), use of the device has grown exponentially. As of mid-2010, more than 188,000 people worldwide have received a cochlear implant system (2). Recent developments in the manufacturing of cochlear implants by the market leader, Cochlear Limited (based in Australia), have resulted in an aim to provide electronically stable models (3).
We detail, derive and correct the technical use of the solid angle variable identified in formal guidance that relates skyshine calculations to dose-equivalent rate.
Abstract -- In order to determine a mouse's dose accurately and prior to engaging in live mouse radiobiological research, a tissue-equivalent tumor-bearing phantom mouse was constructed and bored to accommodate detectors. Comparisons were made among four different types of radiation detectors, each inserted into the mouse phantom for radiation measurement under a 6 MV linear accelerator beam.
Skyshine radiation emanating from medical accelerator facilities is a phenomenon not well understood.
In the process of radiation oncology department accreditation, surveyors pay close attention to continuous quality improvement in the clinical section.
As promulgated by the Nuclear Regulatory Commission, packaging regulations for radioactive material are confusing (e.g., “activity” vs “contained” activity vs “total” activity). As a consequence, medical physicists are forced to secondguess the intent of the regulations.
Recent improvements to the functionality and stability of implantable pacemakers and cardioverter-defibrillators involve changes that include efficient battery power consumption and radiation hardened electrical circuits. Manufacturers have also pursued MRI-compatibility for these devices
Vascular access ports are used widely in the administering of drugs for radiation oncology patients. Their dosimetric effect on radiation therapy delivery in photon beams has not been rigorously established. In this work, the effects on external beam fields when any of a variety of vascular access ports were included in the path of a high energy beam are studied. This study specifically identifies sidescatter and backscatter consequences as well as attenuation effects.
Edited by Oliver Vonend & Siegfried Eckert
Michael Gossman is the author of Chapter 9: Clinical Concerns For and Strategies With Pacemakers in Radiation Oncology
Authors: Todd Pawlicki, et al; Editors; Michael Gossman (Ch. 19), et al
This comprehensive work highlights benefits of quality techniques, approaches to implementation, and guidelines for specific quality assurance steps related to equipment and procedures used in radiotherapy. After an overview of manufacturing and engineering techniques, the text addresses quality and safety issues in radiotherapy from both the physician and physicist viewpoints.